Dr. Parenkumar I. Patel, M.D.
Internal Medicine (Internal Medicine Physician)
At a glance
- Years since graduation
- 25
- In the NPI registry since
- 2009
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2009Registered with an NPI (national billing number; not a license date)
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Internal Medicine Physician primary
FL license ME112660
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Adventhealth Wesley Chapel Wesley Chapel, FL
Medical groups
- Wesley Chapel Medical Care (2 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare prescriptions
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 17 companies reported 48 payments worth $979 in total to this clinician.
| Novo Nordisk Inc | $188 |
|---|---|
| AstraZeneca Pharmaceuticals LP | $159 |
| Lilly USA, LLC | $122 |
| Pfizer Inc. | $119 |
| Shield Therapeutics Inc | $66.43 |
| Bayer HealthCare Pharmaceuticals Inc. | $54.92 |
| Corcept Therapeutics | $46.06 |
| AbbVie Inc. | $31.39 |
| Food and Beverage | $979 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 2 industry-funded studies in 2025, from 2 companies. The companies reported $231,630 in research payments for these studies, mostly to the institutions running them.
- A master protocol to investigate the efficacy and safety of orforglipron once daily in participants with hypertension and obesity or overweight: randomized, double-blind, placebo-controlled trials (attain-hypertension…
Eli Lilly and Company - A Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes and Inadequate Glycemic Control With Insulin Glargine, With or Without Metformin and/or SGLT-2 Inhibitor
Eli Lilly Export S.a. Puerto Rico Branch · Completed · NCT06109311
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.